About GRO Biosciences
GRO Biosciences is a company based in Boston (United States) founded in 2016.. GRO Biosciences has raised $91.15 million across 6 funding rounds from investors including Bayer, Atlas Venture and Redmile Group. The company has 22 employees as of December 31, 2022. GRO Biosciences offers products and services including GRO Platform, ProGly Programs, and Biofoundry. GRO Biosciences operates in a competitive market with competitors including Insitro, Certara, HotSpot Therapeutics, CytoReason and TOLREMO therapeutics, among others.
- Headquarter Boston, United States
- Employees 22 as on 31 Dec, 2022
-
Sectors
Healthcare
-
Phone
*********
-
Website
*********
-
Social
*********
- Legal Name Gro Biosciences Inc
-
Annual Revenue
-
Net Profit
-
EBITDA
-
Total Equity Funding
$91.15 M (USD)
in 6 rounds
-
Latest Funding Round
$60.3 M (USD), Series B
Jul 18, 2024
-
Investors
Bayer
& 7 more
-
Employee Count
22
as on Dec 31, 2022
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of GRO Biosciences
GRO Biosciences offers a comprehensive portfolio of products and services, including GRO Platform, ProGly Programs, and Biofoundry. The company's diverse product and service offerings are designed to meet the evolving needs of its customers, address market demands, and provide comprehensive solutions that drive value creation and customer satisfaction across various segments and use cases.
Enables access to non-standard amino acids for improved protein therapeutics.
Focuses on reversing autoimmunity via pre-glycosylated amino acids.
Supports production of advanced protein chemistries.
Unlock access to complete
Unlock access to complete
Funding Insights of GRO Biosciences
GRO Biosciences has successfully raised a total of $91.15M across 6 strategic funding rounds. The most recent funding activity was a Series B round of $60.3 million completed in July 2024. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 6
- Last Round Series B — $60.3M
-
First Round
First Round
(21 Sep 2017)
- Investors Count 8
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2024 | Amount | Series B - GRO Biosciences | Valuation | Atlas Venture , Access Industries | |
| Nov, 2021 | Amount | Series A - GRO Biosciences | Valuation | Bayer , Redmile Group | |
| Sep, 2020 | Amount | Grant - GRO Biosciences | Valuation |
investors |
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in GRO Biosciences
GRO Biosciences has secured backing from 8 investors, including venture fund and institutional investors. Prominent investors backing the company include Bayer, Atlas Venture and Redmile Group. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Venture capital firm investing in life science and biotechnology sectors
|
Founded Year | Domain | Location | |
|
Digitalis Ventures is engaged in health-focused investments.
|
Founded Year | Domain | Location | |
|
Early-stage technology investments are targeted by this venture capital firm.
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by GRO Biosciences
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
Financial Statements - GRO Biosciences
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Gro Biosciences Comparisons
Competitors of GRO Biosciences
GRO Biosciences operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Insitro, Certara, HotSpot Therapeutics, CytoReason and TOLREMO therapeutics, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
An AI-enabled platform is developed for infectious disease treatment.
|
|
| domain | founded_year | HQ Location |
Provider of a platform for in silico drug discovery and consulting services
|
|
| domain | founded_year | HQ Location |
Developer of a platform for protein function analysis
|
|
| domain | founded_year | HQ Location |
Immune system-based drugs are discovered via biological data analytics.
|
|
| domain | founded_year | HQ Location |
Anti-cancer small molecules are developed to target drug resistance pathways.
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Latest news on Gro Biosciences
Frequently Asked Questions about GRO Biosciences
When was GRO Biosciences founded?
GRO Biosciences was founded in 2016 and raised its 1st funding round 1 year after it was founded.
Where is GRO Biosciences located?
GRO Biosciences is headquartered in Boston, United States. It is registered at Boston, Massachusetts, United States.
Who is the current CEO of GRO Biosciences?
Daniel Mandell is the current CEO of GRO Biosciences.
Is GRO Biosciences a funded company?
GRO Biosciences is a funded company, having raised a total of $91.15M across 6 funding rounds to date. The company's 1st funding round was a Grant of $1M, raised on Sep 21, 2017.
How many employees does GRO Biosciences have?
As of Dec 31, 2022, the latest employee count at GRO Biosciences is 22.
What does GRO Biosciences do?
GRO Biosciences was founded in 2016 and is based in Boston, United States. Operations focus on the synthetic biology sector, where computational biology is integrated with genetic recoding to reprogram organisms and biomaterials. This approach is used to simplify biological systems and improve their performance. Tools and methods are provided for applications in biomaterial engineering and organism modification.
Who are the top competitors of GRO Biosciences?
GRO Biosciences's top competitors include Insitro, HotSpot Therapeutics and Certara.
What products or services does GRO Biosciences offer?
GRO Biosciences offers GRO Platform, ProGly Programs, and Biofoundry.
Who are GRO Biosciences's investors?
GRO Biosciences has 8 investors. Key investors include Bayer, Atlas Venture, Redmile Group, Digitalis Ventures, and Innovation Endeavors.
Book a demo & talk to our team
Share a few details and we’ll reach out to schedule a session.